版本:
中国

BRIEF-FDA accepts supplemental new drug application (SNDA) for vraylar

March 8 Allergan Plc

* FDA accepts supplemental new drug application (SNDA) for vraylar (cariprazine)

* Application seeks to expand vraylar label to include Phase 3 clinical data for maintenance treatment of schizophrenia Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐